A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Number of participants with dose-limiting toxicity (DLT), as defined in the protocol (Part A only)

  Measured over: From first dose of study intervention to 28 days post first dose

• Number of participants with Adverse Events and Serious Adverse Events

  Measured over: From first dose of study intervention up to 37 days after the last dose of study treatment

• Number of participants with Adverse Events leading to discontinuation of study intervention

  Measured over: From first dose of study intervention up to 37 days after the last dose of study treatment

• Clinically significant changes from baseline in vital signs.

  Measured over: From first study dose up to 37 days after the last dose of study treatment

• Clinically significant changes from baseline in physical examination.

  Measured over: From first dose of study intervention up to 37 days after the last dose of study treatment

• Clinically significant changes from baseline in ECOG PS.

  Measured over: From first dose of study intervention up to 37 days after the last dose of study treatment

• Clinically significant changes from baseline in ECGs.

  Measured over: From first dose of study intervention up to 37 days after the last dose of study treatment

• Clinically significant changes from baseline in laboratory parameters.

  Measured over: From first dose of study intervention up to 37 days after the last dose of study treatment

• Proportion of participants achieving a ≥50% decrease in PSA from baseline (PSA50) (Part B only)

  Measured over: From first dose of study intervention up to 14 days after the last dose of study treatment

Changes Tremor has spotted